U.S. Markets closed

Regeneron, Bayer reports positive Phase 3 results for Eylea

Regeneron Pharmaceuticals (REGN) and Bayer HealthCare (BAYRY) announced positive top-line results for EYLEA Injection from the Phase 3 MYRROR study in myopic choroidal neovascularization. In this trial, patients receiving EYLEA at an initial dose of 2 milligrams, followed by treatment on an as-needed basis, had a mean improvement in best-corrected visual acuity from baseline at week 24 of 12.1 letters, compared to a loss of 2.0 letters in patients receiving sham injections. The most common adverse events observed in the MYRROR trial that occurred with a frequency of 2% or more were conjunctival hemorrhage, dry eye, eye pain, headache and nasopharyngitis.